HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022
19 avr. 2022 07h33 HE
|
HCW Biologics, Inc
Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer Debut of preclinical data related to age-associated diseases MIRAMAR, Fla.,...
HCW Biologics’ Founder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year
13 déc. 2021 07h31 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel...
HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer
28 oct. 2021 07h00 HE
|
HCW Biologics, Inc
Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company’s lead product candidate, in refractory, advanced/metastatic pancreatic cancer MIRAMAR, Fla., Oct. 28, 2021...
HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic
24 août 2021 07h32 HE
|
HCW Biologics, Inc
Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform Preclinical Data Demonstrated HCW9218 Antitumor Activity as Single-Agent Monotherapy and as an Adjunct to Enhance...
HCW Biologics’ Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform
17 août 2021 07h32 HE
|
HCW Biologics, Inc
TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells MIRAMAR, Fla., Aug. 17, 2021 (GLOBE...
HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights
13 août 2021 07h10 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel...
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering
22 juil. 2021 16h05 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing...
HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering
19 juil. 2021 18h39 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing...